At the news
? BULLISHIMPACT 5/10 PRESS-RELEASE filed Jul 21, 2026 at 17:00 ET
Telix announced peer-reviewed publication of ProstACT SELECT Phase 1 results in Cancers, confirming that 68Ga-PSMA-PET imaging can select patients for TLX591-Tx therapy. The data show a median radiographic progression-free survival of 8.8 months in evaluable patients, a manageable safety profile, and prolonged tumor retention. This is a positive scientific validation for TLX591-Tx's patient-selection strategy and supports the ongoing Phase 3 ProstACT Global trial, but does not change the binary regulatory or commercial outlook for the asset.
- ProstACT SELECT Phase 1 results published in peer-reviewed journal Cancers.
- Median radiographic progression-free survival (rPFS) of 8.8 months reported in evaluable patients.
- TLX591-Tx demonstrated manageable safety profile and prolonged tumor retention with low salivary gland irradiation.
- Publication supports patient-selection strategy for ongoing Phase 3 ProstACT Global trial in mCRPC.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access